SCHEMBL3983149

SCHEMBL3983149

O=C(Nc1cccc(Cl)c1)Oc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.66
MEN1 O00255 4/20 0.66
NPC1 O15118 3/20 0.66
RAB9A P51151 3/20 0.66
CYP1A2 P05177 1/20 0.66
FAAH O00519 1/20 0.63
TRPV1 Q8NER1 1/20 0.63
MAPT P10636 4/20 0.63
HTT P42858 3/20 0.63
LMNA P02545 2/20 0.63
POLB P06746 1/20 0.59
HPGD P15428 1/20 0.59
ALOX15 P16050 1/20 0.59
ALDH1A1 P00352 4/20 0.59
KDM4E B2RXH2 1/20 0.56
GAA P10253 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
BCHE P06276 1/20 0.55
ACHE P22303 1/20 0.55
RAD51 Q06609 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30063912 1.00 KMT2A (0.66) KMT2AMEN1NPC1RAB9ACYP1A2
SCHEMBL20380069 0.89 NPC1 (0.68) KMT2AMEN1NPC1RAB9ACYP1A2
SCHEMBL8048626 0.88 CYP1A2 (0.76) KMT2AMEN1RAB9ACYP1A2FAAH
SCHEMBL2450691 0.88 HPGD (0.56) KMT2AMEN1NPC1RAB9ACYP1A2
SCHEMBL3990068 0.87 MAPT (0.59) KMT2AMEN1RAB9ACYP1A2MAPT
SCHEMBL3792715 0.86 SMN1; SMN2 (0.68) KMT2AMEN1NPC1RAB9ACYP1A2
SCHEMBL6480149 0.84 CNR1 (0.66) KMT2AMEN1CYP1A2POLB
Chlorpropham SCHEMBL11800746 0.83 HPGD (0.74) KMT2AMEN1NPC1RAB9ACYP1A2
Phenyl Phenylcarbamate SCHEMBL272994 0.82 ALDH1A1 (0.76) KMT2AMEN1RAB9ACYP1A2FAAH
SCHEMBL1569274 0.82 CYP1A2 (0.68) KMT2AMEN1CYP1A2FAAHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222450-A1 Process for preparing carbamates COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-10-06 US claimed
WO-2005063698-A1 PROCESS FOR PREPARING CARBAMATES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2005-07-14 WO claimed
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 US disclosed
US-20250163024-A1 CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-05-22 US disclosed
EP-4460306-A2 TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) Dana-Farber Cancer Institute, Inc. (US) 2024-11-13 EP disclosed
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2024-08-08 US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 US disclosed
EP-4277901-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 EP disclosed
EP-4278014-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 EP disclosed
US-20230348418-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2023-11-02 US disclosed
WO-2023133260-A2 CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-07-13 WO disclosed
EP-1380574-A1 9-aminoacridine derivates and process for the preparation thereof Samjin Pharmaceutical Co., Ltd. (KR) 2004-01-14 EP disclosed
US-6620936-B2 Antitumor agents, topoisomerase inhibitors, notoxic SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-16 US disclosed
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2002-08-15 US disclosed
CN-1254281-A HIV and cancer treatment PROCTER & GAMBLE (US) 2000-05-24 CN disclosed
US-5003106-A Antiatherosclerotic ureas and thioureas AMERICAN CYANAMID COMPANY (US) 1991-03-26 US disclosed
US-4623662-A ANTICHOLESTEROL, ANTILIPEMIC AMERICAN CYANAMID COMPANY (US) 1986-11-18 US disclosed
US-4396621-A ANALGESICS, ANTIIMFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1983-08-02 US disclosed
US-4320138-A ANTIINFLAMMATORY AGENTS FOR ARTHRITIS, GOUT CIBA-GEIGY CORPORATION (US) 1982-03-16 US disclosed
US-4260779-A ANALGESICS, ANTIINFLAMMATORY, DIURETICS CIBA-GEIGY CORPORATION (US) 1981-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163024-A1 CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SMARCE1, SMARCA4, SMARCA2 KMT2A 74/4885MEN1 1691/4885NPC1 4013/4885
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 KMT2A 1951/4885MEN1 186/4885NPC1 285/4885
US-20230348418-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 KMT2A 1988/4885MEN1 180/4885NPC1 269/4885
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof ALKBH1, ADCY9, CCR9 KMT2A 1780/4885MEN1 1879/4885NPC1 1076/4885
US-20050222450-A1 Process for preparing carbamates CPS1, OTC, RCC2 KMT2A 1291/4885MEN1 2336/4885NPC1 2863/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 KMT2A 1951/4885MEN1 186/4885NPC1 285/4885
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MYC, MYCBP, GSPT1 KMT2A 1755/4885MEN1 104/4885NPC1 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.